Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables
|Chikungunya virus disease||37||0.01|
|Eastern equine encephalitis virus disease|
|Jamestown Canyon virus disease|
|La Crosse virus disease|
|Powassan virus disease|
|St. Louis encephalitis virus disease|
|West Nile virus disease|
|Western equine encephalitis virus disease|
|Other (wound & unspecified)||35||0.01|
|Candida auris, clinical †||255||0.08|
|Carbapenemase-producing carbapenem-resistant Enterobacteriaceae||1,848||0.61|
|Chlamydia trachomatis infection||1,579,837||479.49|
|Coronavirus Disease 2019 (COVID-19)|
|Dengue virus infections ¶|
|Ehrlichiosis and Anaplasmosis|
|Anaplasma phagocytophilum infection||3,637||1.15|
|Ehrlichia chaffeensis infection||1,178||0.37|
|Ehrlichia ewingii infection||21||0.01|
|Haemophilus influenzae, invasive disease|
|All ages, all serotypes||2,996||0.91|
|Age <5 years|
|Hantavirus infection, non-hantavirus pulmonary syndrome **||2||0.00|
|Hantavirus pulmonary syndrome||14||0.00|
|Hemolytic uremic syndrome post-diarrheal||167||0.05|
|Hepatitis, Viral Disease ††|
|Human immunodeficiency virus diagnoses||25,007||7.59|
|Influenza-associated pediatric mortality||171||0.23|
|Invasive pneumococcal disease §§|
|Age <5 years||561||0.21|
|Novel Influenza A virus infections||—||—|
|Poliovirus infection, nonparalytic||—||—|
|Rubella, congenital syndrome||—||—|
|Salmonella Paratyphi infection ¶¶¶||75||0.02|
|Salmonella Typhi infection ****||182||0.06|
|Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) ††††||45,442||13.79|
|Severe acute respiratory syndrome-associated coronavirus disease||—||—|
|Shiga toxin-producing Escherichia coli (STEC)||9,922||3.01|
|Spotted fever rickettsiosis|
|Streptococcal toxic shock syndrome||224||0.11|
|Total, all stages §§§§||133,933||40.65|
|Primary and secondary||41,654||12.64|
|Toxic shock syndrome (other than Streptococcal)||24||0.01|
|Vancomycin-intermediate Staphylococcus aureus||45||0.02|
|Vancomycin-resistant Staphylococcus aureus *****||1||0.00|
|Viral hemorrhagic fevers|
|Crimean-Congo hemorrhagic fever virus||—||—|
|Zika virus disease, congenital †††††||—||—|
|Zika virus disease, non-congenital||4||0.00|
|Zika virus infection, congenital †††††||—||—|
|Zika virus infection, non-congenital||19||0.01|
- —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
- * For population data, see Table 8. Also see Notes #3 and #7.
- † Candida auris colonization/screening cases are not included in this table. These data are available on the Mycotic Diseases Branch's Tracking Candida auris page (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html)
- § Please see Note #11.
- ¶ Counts include confirmed and probable dengue cases.
- ** Case counts may include Old World hantavirus infections, such as Seoul virus.
- †† Chronic hepatitis B and chronic hepatitis C data are not included in NNDSS tables but reported case counts are included in the annual Viral Hepatitis Surveillance Report, 2020, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
- §§ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
- ¶¶ In 2020, the CSTE case definition changed such that cases diagnosed by PCR were classified as confirmed, whereas previously those cases were classified as suspect and did not meet the publication/print criteria.
- *** Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately.
- ††† Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
- §§§ Beginning in 2020, confirmed and probable plague cases are being combined and published. In 2019, only confirmed plague cases were published.
- ¶¶¶ Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
- **** Beginning in January 2019, cases began to be reported as Salmonella Typhi infection. In previous years, cases were reported as typhoid fever.
- †††† Beginning in January 2019, cases began to be reported as salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
- §§§§ Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations) and congenital syphilis.
- ¶¶¶¶ Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth.
- ***** Vancomycin-resistant Staphylococcus aureus cases reported in this table may not have been verified by CDC. CDC verified 0 vancomycin-resistant Staphylococcus aureus cases in 2020.
- ††††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).